Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda Duska, Marta A. Crispens, Alexander Olawaiye, Ira Winer, Lisa Barroilhet, Siqing Fu, Michael McHale, Russell J. Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne Quinn, Brittany Bowes, Alan D. D’Andrea, Geoffrey I. Shapiro, Ursula A. Matulonis
Topics & Concepts
GemcitabineMedicineOncologyInternal medicineClinical endpointCarboplatinOvarian cancerClinical trialCancerChemotherapyCisplatinOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyProtein Degradation and Inhibitors